

Supplementary Information for

Elucidating aromatic acid tolerance at low pH in *Saccharomyces cerevisiae* using adaptive laboratory evolution

Rui Pereira, Elsayed T. Mohamed, Mohammad S. Radi, Markus J. Herrgård, Adam M. Feist, Jens Nielsen, Yun Chen

Corresponding author: Yun Chen

Email: yunc@chalmers.se

# This PDF file includes:

Supplementary text Figure S1 Tables S1 to S8 SI References

## Supplementary Information Text

# Materials and Methods

#### Strains, media and DNA handling

The strains used and constructed in this work are listed in Table S6. The strain GL01 (1) was used for all the ALE experiments because the presence of the G418 resistance marker (KANMX) and a GFP gene (under the control of a *GAL1* promoter) allowed to check the evolving populations for possible contamination during the ALE. Reverse engineering of tolerance mutations was performed on the strain IMX585 (2), which has a copy of Cas9 integrated in a CEN.PK113-7D background. The coumaric acid production strains tested in this work were based on strains obtained from (3). *Escherichia coli* DH5 $\alpha$  was used for plasmid isolation and maintenance using the competence and transformation procedures developed by (4) as described in (5).

The oligonucleotides used here are listed in Table S7 and were purchased from Eurofins Genomics. High fidelity PCR was performed with Phusion polymerase (ThermoFisher) and colony PCR was performed with DreamTaq DNA polymerase (ThermoFisher). The appropriate GeneJET kits from ThermoFisher were used for plasmid extraction and PCR product purification.

Plasmid selection and maintenance in *E. coli* was performed in LB medium containing 10 g/L of peptone, 10 g/L of NaCl, 5 g/L of yeast extract and supplemented with 100 mg/L of ampicillin sodium salt. Solid LB was prepared by adding 16 g/L of agar to the recipe above. The selection of *S. cerevisiae* strains expressing the KANMX marker was done in YPD medium containing 10 g/L yeast extract, 20 g/L of peptone, 20 g/L of glucose and supplemented with 200 mg/L G418 disulfate (Sigma-Aldrich). Selection of strains expressing the *amdSYM* marker was performed in medium with 0.6 g/L of acetamide as

the only nitrogen source as described in (6). URA<sup>+</sup> strains were selected in Synthetic Dextrose (SD) medium containing 6.7 g/L of yeast nitrogen base without amino acids (ForMedium), 0.77 g/L of complete supplement mixture without uracil (ForMedium) and 20 g/L of glucose. Solid versions of each medium were prepared by adding 20 g/L of agar. ALE experiments and growth tests were performed in the minimal medium described by (7), which contained 20 g/L of glucose, 5 g/L of (NH4)<sub>2</sub>SO<sub>4</sub>, 3 g/L of KH<sub>2</sub>PO<sub>4</sub>, 0.5 g/L of MgSO<sub>4</sub>·7H<sub>2</sub>O, 1 mL/L of vitamin solution and 1 mL/L of trace metal solution. The pH of the medium was adjusted to 3.5 with HCl and buffered at this pH by adding 140 mL/L of 0.5 M citrate solution and 60 mL/L of 1M Na<sub>2</sub>HPO<sub>4</sub>. For testing strains in alternative nitrogen sources, (NH4)<sub>2</sub>SO<sub>4</sub> was replaced with 6.6 g/L of K<sub>2</sub>SO<sub>4</sub> and the required amino acid was added in the appropriate concentration (5 g/L of L-phenylalanine, 5g/L of L-tryptophan or 0.5 g/L of L-tyrosine). Coumaric acid, ferulic acid, phenylacetic acid and indoleacetic acid were purchased from Sigma-Aldrich and added to the culture media in the appropriate concentration of 10 g/L.

## Strain construction

The list of plasmids used and constructed in this study is provided in Table S8. The reverse engineered strains containing deletions, point mutations and insertions were constructed using the single gRNA method described elsewhere (2). The primers used for the deletion of ESBP6 and **PDR12** were designed using the Yeastriction tool (http://yeastriction.tnw.tudelft.nl). For each deletion a set of six oligonucleotides were ordered: two complementary 120 bp oligonucleotides with the desired 20 bp gRNA target sequence (without PAM site) flanked by two 50 bp sequences homologous to the gRNA site on plasmid pMEL13 (2); two complementary 120 bp oligonucleotides composed of 60 bp homologous to the region upstream of the coding sequence of the target gene and 60

bp homologous to the region downstream of the coding sequence of the target gene; and two colony PCR primers for verifying the desired region was removed for the genome. Each pair of complementary oligonucleotides were mixed in equimolar amounts and annealed by heating the mixture to 95 °C for five minutes and allowing it to cool down at room temperature. In order to generate plasmids expressing the desired gRNA, each double stranded gRNA insert was cloned into the plasmid pMEL13 (linearized with primers 1 and 2) using CPEC cloning (8), yielding plasmids pMEL13-ESBP6-KO and pMEL13-PDR12-KO. The sequence of each plasmid was confirmed by sequencing with primer 3. Single deletion strains for either gene were obtained by transforming 100 ng of the desired gRNA plasmid with 2 μg of double stranded repair fragment into the strain IMX585 using the high-efficiency protocol described by (9). The transformation mixture was spread on plates containing G418 and individual colonies tested for the deletion using colony PCR. The deletion of *ESBP6* was performed with the primers 4-7 and confirmed with the primers 8/9. *PDR12* was deleted with the primers 10-13 and tested using the flanking primers 14/15.

The introduction of single nucleotide substitutions into the strain IMX585 was done using the same protocol described for deletions but with the following modifications: the gRNA site was selected based on the proximity to the substitution site and the possibility of inactivating the PAM site using a synonymous substitution; and the two complementary oligonucleotides for the repair fragment were designed to introduce the desired mutation and inactivating the PAM site. The plasmids expressing the gRNAs for introducing each mutation were obtained using CPEC cloning (8) using linearized pMEL13 plasmid and the appropriate double stranded repair fragment, resulting in: pMEL13-ARO80-706, pMEL13-ARO80-910 and pMEL13-NRG1-226. The mutation *ARO80*<sup>S706T</sup> was introduced using primers 16-19, amplified using primers 20/21 and sequenced with primer 20. The *ARO80*<sup>E910D</sup> mutation was introduced using primers 22-25, amplified using primers 20/21

and sequenced with primer 21. The NRG1<sup>H226N</sup> mutation was introduced using primers 26-29, amplified using primers 30/31 and sequenced with primer 30. The double mutants  $ARO80^{S706T} + \Delta ESBP6$  and  $ARO80^{E910D} + \Delta ESBP6$  were obtained by deleting the gene ESBP6 on each of the ARO80 point mutation strains using the protocol described above. For the integration of ESBP6 under the control of a TEF1 promoter on the site X-2 of chromosome X (10) the same protocol described for gene deletions was used but in this case using a gRNA plasmid designed to create a double strand break on the desired integration site (pQC059) (3). The integration cassette was obtained by amplifying the following DNA segments: the region downstream of the site X-2 was amplified from plasmid pX-2 (10) using primers 32/33, the TEF1 promoter was amplified from plasmid pSPGM1 (11) using primers 34/35, the ESBP6 coding sequence was amplified from the genomic DNA of CEN.PK113-7D using primers 36/37 and the ADH1 terminator and upstream region of the site X-2 were amplified from plasmid pX-2 using primers 40/41. To integrate the ESBP6 cassette into the strain IMX585, an equimolar amount of each DNA segment described above (total amount of 2  $\mu$ g) and 200 ng of pQC059 were transformed into the target strain using the high-efficiency protocol described by (9). Isolated colonies from the transformation were tested by colony PCR using primers flanking the integration region (primers 40/41) and confirmed by sequencing.

The strains QL01\_ESBP6 and QL38\_ESBP6 were constructed by integrating *ESBP6* under the control of the *TEF1* promoter on site XI-5 of chromosome XI (10) in strains QL01 and QL38 (3) respectively. The integration cassette was obtained by amplifying the following DNA fragments: the region upstream of the site XI-5 together with the *ADH1* terminator were amplified from plasmid pIRP01 (12) with primers 42/43, the *TEF1* promotor together with the *ESBP6* coding sequence and *ADH1* terminator were amplified from the genomic DNA of strain ESBP6\_OE with primers 44/45 and the *TEF1* promoter together with KIURA3 marker and the region downstream of the site XI-5 were amplified

from the plasmid pIRP01 (12) with the primers 46/47. Equimolar amounts of each purified fragment were mixed together for a total of 2  $\mu$ g of DNA and transformed into QL01 or QL38 using the high-efficiency protocol described by (9). The transformation mix was plated on SD medium without uracil and a selection of clones was tested for the correct integration using primers 44/48. The integrated region was sequenced to confirm there were no errors. The strains QL01\_URA and QL38\_URA were constructed by integrating a cassette including only the KIURA3 marker on site XI-5 of chromosome XI in strains QL01 and QL38 (3) respectively. The integration cassette was obtained by amplifying a DNA fragment including the region upstream of the site XI-5 together with the KIURA3 marker and the region downstream of the site XI-5 with primers 42/46 from plasmid pXI-5 (10). 2  $\mu$ g of the DNA cassette were transformed into QL01 or QL38 using the high-efficiency protocol described by (9), the transformation mix was plated on SD medium without uracil and a selection of clones was tested for the correct integration using primers 44/48. The integrated region marker and the region downstream of the site XI-5 with primers 42/46 from plasmid pXI-5 (10). 2  $\mu$ g of the DNA cassette were transformed into QL01 or QL38 using the high-efficiency protocol described by (9), the transformation mix was plated on SD medium without uracil and a selection of clones was tested for the correct integration using primers 44/48. The integrated region was sequenced to confirm there were no errors.

## Adaptive laboratory evolution

Adaptive laboratory evolution experiments were conducted on an automated platform using a liquid handling robot as described previously (13, 14). Five independent experiments per aromatic acid were serially propagated (400 µL to 900 µL passage volume) in 17 mL (working volume) flasks of minimal medium supplemented with 10 g/L glucose, kept at 30°C through placement in a heat block and aerated by magnetic stirrers at 1200 rpm. Optical density (OD600nm) for each flask was monitored with a Tecan Sunrise plate reader as a proxy for cell density. Growth rates were calculated automatically using a best fit approximation for the growth using a three-phase model for lag, exponential growth, and stationary phase. Growth rates and final flask densities were recorded for each flask along with the quality of the fit for the growth model. The timing for

increasing the concentration of each aromatic acid was decided according to the methodology described elsewhere (1).

# Growth screening

The growth characterization of the post evolution mutants and reverse engineered strains was performed in a Growth profiler 960 (Enzyscreen) using 96-half-deep well microplates (with transparent bottom) with a total culture volume of 250 µl, agitation at 250 rpm, temperature controlled at 30 °C and initial OD600 of 0.05. Three biological replicates (each with 2-3 technical replicates) for each strain were tested. Image scans were taken every 30 minutes and green pixels were converted to OD600 using a calibration curve created by filling ten wells with cell suspensions of known OD600 between zero and ten. The maximum growth rates for each strain were calculated by finding the highest slope in plots of the natural logarithm of the OD600 versus time.

## gDNA extraction and sequencing

Chosen clones isolated from the evolved populations were cultivated overnight in 15 mL of YPD medium up to an OD600 close to four. The Blood & Cell Culture DNA Mini Kit (Qiagen) was used to extract genomic DNA from 3 mL of the overnight yeast culture ( $\sim$ 5 × 10<sup>8</sup> cells) using the protocol recommended by the manufacturer. Sequencing was performed with the NextSeq (High output kit) with 2x150 paired-end reads targeting a genome coverage of 100x per sample.

#### Sequencing data analysis

Mutations in evolved clones were identified using breseq 0.30.2 (15) with Bowtie 2.2.8 as aligner (16). Around nine million short reads for each strain (in fastq format) were aligned to the reference genome of CEN.PK113-7D (17) modified as follows: the GFP and KANMX

genes were added to chromosome XI, the annotations from the genome of *S. cerevisiae* S288c (R64-2-1) were transferred to the CEN.PK113-7D genome using RATT (18), the genome was polished by using breseq with the sequencing data for the strain GL01 and the identified mutations were patched to it. Each sample was analyzed by running breseq in consensus mode with the option "junction-alignment-pair-limit" set to 0 (no limit) to ensure all possible new junctions were evaluated. Reads from the reference strain (GL01) were also processed in the same conditions for the identification of false-positives. A custom-made script was used to find if the mutations detected in each mutant strain were false-positives by checking if there was any evidence for the same mutation occurring in the reference strain. To detect large-scale chromosome duplication/deletion, each chromosome coverage map generated by breseq was inspected visually.

#### Phenylacetic acid and phenylethanol quantification

Fusel acid and fusel alcohol production tests were performed in 100 mL shake-flasks containing 25 mL of the minimal medium described in the "Strains, media and DNA handling" section with 20g/L glucose or 10 g/L ethanol, the pH adjusted to 3.5 and 5 g/L of L-phenylalanine. Cultures were inoculated in triplicate with an initial OD600 of 0.05 and shaken at 200 rpm in an orbital incubator, at 30 °C for 96 hours. Extracellular concentration of phenylacetic acid and phenylethanol in cultures of a reference strain (IMX585) and a double deletion mutant ( $\Delta$ PDR12 +  $\Delta$ ESBP6) by HPLC using a method previously described by Li et al. (3).

#### Coumaric acid production tests

Coumaric acid production tests were performed in 100 mL shake-flasks containing 20 mL of the minimal medium described in the "Strains, media and DNA handling" section without glucose and pH adjusted to 3.5. At the beginning of the culture six tablets of FeedBeads

(SMFB08001, Kuhner Shaker, Basel, Switzerland) were added and the culture inoculated with an initial OD600 of 0.05. Cultures were shaken at 200 rpm in an orbital incubator, at 30 °C during 96 hours. To the medium used for strains QL38\_URA and QL38\_ESBP6 1% of galactose was also added to induce genes controlled by the GAL promoters. *p*-coumaric acid was quantified by mixing 1 mL of culture with 1 mL of absolute ethanol, thorough vortexing, centrifuging at 14000 x g and analyzing the supernatant using HPLC as described by Li et al. (3).



Fig. S1. Influence of PDR12/ESBP6 on fusel acid tolerance. A – Growth curves in medium with 0.1 g/L of indoleacetic acid for a reference strain (IMX585) in comparison to a PDR12 deletion mutant ( $\Delta$ PDR12) and a double mutant lacking *PDR12* and displaying the overexpression of *ESBP6* ( $\Delta$ PDR12 + ESBP6\_OE). Cells were grown in 96-well plates with a volume of 250 µL in medium with 0.1 g/L of indoleacetic acid. B - Growth curves in medium with 0.5 g/L of phenylacetic acid and 0.5 g/L of L-tyrosine or 5 g/L of L-tryptophan as nitrogen source for a reference strain (IMX585) in comparison to a PDR12 deletion mutant ( $\Delta$ PDR12). Cells were grown in 96-well plates with a volume of 250 µL in medium with 5 g/L of L-tryptophan or 0.5 g/L of L-tyrosine as nitrogen source and 0.5 g/L of phenylacetic acid. C - Growth curves in medium with 0.1 g/L of indoleacetic acid and 5 g/L of L-tryptophan as nitrogen source for a reference strain (IMX585) in comparison to a PDR12 deletion mutant ( $\Delta$ PDR12) and a double deletion mutant lacking PDR12 and ESBP6 ( $\Delta$ PDR12 +  $\Delta$ ESBP6). Cells were grown in 96-well plates with a volume of 250 µL in medium with 5 g/L of L-tryptophan as nitrogen source and 0.1 g/L of indoleacetic acid. All growth curves were performed for three biological replicates (each with two technical replicates) and the average OD600s are shown as solid lines with the interval encompassing the standard deviation represented as a shaded area.

**Table S1.** Growth-rates and maximum optical densities for a wild-type strain and individual mutants

 evolved in coumaric acid

	Strain	growth-rate	Max. OD
WT	GL01	0.02 ± 0.01	$0.26 \pm 0.05$
	CA1.5	0.31 ± 0.00	10.33 ± 0.57
C-EVO1	CA1.6	$0.35 \pm 0.00$	10.01 ± 0.56
	CA1.8	0.34 ± 0.01	9.95 ± 0.27
	CA2.2	0.34 ± 0.01	10.33 ± 0.52
C-EVO2	CA2.5	$0.32 \pm 0.00$	10.34 ± 0.44
	CA2.8	0.32 ± 0.01	10.37 ± 0.37
	CA3.1	$0.24 \pm 0.00$	9.99 ± 0.53
C-EVO3	CA3.5	0.35 ± 0.01	9.83 ± 0.32
	CA3.6	0.33 ± 0.01	10.26 ± 0.37
	CA4.2	$0.22 \pm 0.00$	9.79 ± 0.45
C-EVO4	CA4.4	0.25 ± 0.01	10.38 ± 0.09
	CA4.6	0.23 ± 0.01	9.99 ± 0.19
	CA5.1	0.33 ± 0.01	9.97 ± 0.39
C-EVO5	CA5.2	0.34 ± 0.01	10.14 ± 0.21
	CA5.8	0.31 ± 0.00	10.17 ± 0.27
WT (without coumaric acid)	GL01	0.41 ± 0.01	9.20 ± 0.38

	Strain	growth-rate	Max. OD
WT	GL01	$0.00 \pm 0.00$	0.13 ± 0.02
	FA.1.1	0.25 ± 0.01	6.21 ± 0.18
F-EVO1	FA.1.6	0.21 ± 0.00	7.32 ± 0.38
	FA.1.8	0.24 ± 0.01	5.90 ± 0.14
	FA.2.2	0.29 ± 0.01	7.62 ± 0.27
F-EVO2	FA.2.4	0.25 ± 0.01	6.85 ± 0.17
	FA.2.5	0.26 ± 0.01	8.09 ± 0.15
	FA.3.1	0.27 ± 0.01	8.22 ± 0.20
F-EVO3	FA.3.2	0.27 ± 0.00	8.36 ± 0.21
	FA.3.7	0.26 ± 0.01	$7.20 \pm 0.14$
	FA.4.1	0.27 ± 0.01	$6.49 \pm 0.08$
F-EVO4	FA.4.2	0.26 ± 0.01	7.64 ± 0.33
	FA.4.6	0.30 ± 0.01	7.24 ± 0.26
	FA.5.1	$0.23 \pm 0.00$	9.45 ± 0.08
F-EVO5	FA.5.6	$0.24 \pm 0.00$	9.20 ± 0.29
	FA.5.8	$0.23 \pm 0.00$	8.14 ± 0.21
WT (without ferulic acid)	GL01	0.41 ± 0.01	9.20 ± 0.38

**Table S2.** Growth-rates and maximum optical densities for a wild-type strain and individual mutants evolved in ferulic acid

# Table S3. Mutations present in individual mutants evolved in coumaric acid

Strain Gene	CA1.5	CA1.6	CA1.8	CA2.2	CA2.5	CA2.8	CA3.1	CA3.5	CA3.6	CA4.2	CA4.4	CA4.6	CA5.1	CA5.2	CA5.8
Al1										A14T (GCA→ACA), G593S (GGT→AGT)		G593S (GGT→AGT), A14T (GCA→ACA)			
AIM44	I588V (ATT→GTT)	I588V (ATT→GTT)	I588V (ATT→GTT)												
ARO80	S706T (TCC→ACC)	S706T (TCC→ACC)	S706T (TCC→ACC)	A708E (GCG→GAG)	A708E (GCG→GAG)	A708E (GCG→GAG)	R766I (AGA→ATA)	M778T (ATG→ACG)	M778T (ATG→ACG)	R766I (AGA→ATA)	R766I (AGA→ATA)	R766I (AGA→ATA)	M778T (ATG→ACG)	M778T (ATG→ACG)	E777K (GAG→AAG)
ATE1	R217* (CGA→TGA)	R217* (CGA→TGA)	R217* (CGA→TGA)												R217* (CGA→TGA)
CAD1	A14S (GCA→TCA)	A14S (GCA→TCA)	A14S (GCA→TCA)												
CBK1	V397F (GTC→TTC)	V397F (GTC→TTC)	V397F (GTC→TTC)												
COQ1							H318Q (CAC→CAG)			H318Q (CAC→CAG)	H318Q (CAC→CAG)	H318Q (CAC→CAG)			
COX1														(G)9→10, coding (6500/6666 nt)	
CRD1				A97P (GCA→CCA)	A97P (GCA→CCA)	A97P (GCA→CCA)									
CYC8										D161H (GAC→CAC)		D161H (GAC→CAC)			D161H (GAC→CAC)
DNF1								(T)9→10, coding (3860/4716 nt)							
DTR1								T357K (ACA→AAA)							
DTR1														T357K (ACA→AAA)	
EFR3			L212M (TTG→ATG)												
ESL2				M688T (ATG→ACG)											
FIG2							S741* (TCA→TAA)								
FMN1							F32V (TTT→GTT)								
FMP27											T242K (ACA→AAA)				
FRK1	D639E (GAC→GAG)														
FUN26					S125F (TCT→TTT)										
FYV8	V577L (GTT→CTT)														
HAT1									S296T (AGC→ACC)						
HIR2															T531K (ACA→AAA)
HSK3												K28E (AAA→GAA)			
IRA1							T682K (ACA→AAA)			T682K (ACA→AAA)	T682K (ACA→AAA)	T682K (ACA→AAA)			
LYP1	(AT)9→11, coding (2/1836 nt)	(AT)9→11, coding (2/1836 nt)													
MCM16														R51L (CGC→CTC)	
MNN9								N102K (AAC→AAA)							
MTC6											R368* (CGA→TGA)				
NRG1	H226N (CAT→AAT)	H226N (CAT→AAT)	H226N (CAT→AAT)	H192Q (CAT→CAA)	H192Q (CAT→CAA)	H192Q (CAT→CAA)	C219G (TGC→GGC)	C179G (TGC→GGC)	C179G (TGC→GGC)	C219G (TGC→GGC)	C219G (TGC→GGC)	C219G (TGC→GGC)	C179G (TGC→GGC)	C179G (TGC→GGC)	
NUT1												L621F (TTG→TTT)			
PET18															I40I (ATC→ATA)
PUF2					(ATA)14→15, coding (3160/3228 nt)										
RAI1															K256N (AAG→AAT)
RBH2		Δ11172 bp, between Ty1													
RPL28		EIK						L66F (TTG→TTT)							
RTG2							E406Q (GAG→CAG)								
SEC8	I490F (ATT→TTT)	I490F (ATT→TTT)	I490F (ATT→TTT)												
SIP5									C271F (TGC→TTC)						
SPS22		V171F (GTT→TTT)													
STE4				A198E (GCA→GAA)											
STE6														G579G (GGT→GGC)	
SVL3						T258I (ACT→ATT)									
TDP1					M421T (ATG→ACG)										
THI22												D472E (GAC→GAA)			
TRK1											L988F (TTG→TTC)				
WTM1									H143Q (CAC→CAA)				H143Q (CAC→CAA)		
YHL017W												N152K (AAC→AAA)			
YKR005C	A478D (GCT→GAT)														
YLR419W										D449N (GAT→AAT)		D449N (GAT→AAT)			
YLR466C-B									+T, coding (42/117 nt)				+T, coding (42/117 nt)	+T, coding (42/117 nt)	
(chromosome XI)							duplication (223000- 335000)			duplication (223000- 335000)	duplication (223000- 335000)	duplication (223000- 335000)			
(chromosome XIV)				duplication (373000- 427000)	duplication (373000- 427000)	duplication (373000- 427000)	duplication (1-533000)	duplication (373000- 427000)	50 % increase (364000- 515000)	duplication (1-533000)	triplication (373000- 427000) duplication (1-533000)	triplication (373000- 427000) duplication (1-533000)	25% increase (373000- 427000)	duplication (373000- 427000)	triplication (373000- 408000)

Strain Gene	FA1.1	FA1.6	FA1.8	FA2.2	FA2.4	FA2.5	FA3.1	FA3.2	FA3.7	FA4.1	FA4.2	FA4.6	FA5.1	FA5.6	FA5.8
ACE2	H653Q (CAC→CAA)	H653Q (CAC→CAA)	H653Q (CAC→CAA)		H627Y (CAT→TAT)								D592H (GAC→CAC)	D592H (GAC→CAC)	E604* (GAG→TAG)
APN1			A227V (GCT→GTT)												
ARO80	V902L (GTA→TTA)	V902L (GTA→TTA)	V902L (GTA→TTA)	E910D (GAG→GAT)	E910D (GAG→GAT)	E910D (GAG→GAT)	E910D (GAG→GAT)	E910D (GAG→GAT)	E910D (GAG→GAT)	S631N (AGT→AAT)	S631N (AGT→AAT)	S631N (AGT→AAT)	R912G (CGA→GGA)	R912G (CGA→GGA)	R912G (CGA→GGA)
ATE1				R217* (CGA→TGA)	R217* (CGA→TGA)	R217* (CGA→TGA)	R217* (CGA→TGA)	R217* (CGA→TGA)							
AVT1				(T)0 7	(7)0 7		P480A (CCT→GCT)	P480A (CCT→GCT)							
BNA2				(1)6→7, coding (970/1362 nt)	(1)6→7, coding (970/1362 nt)	(1)6→7, coding (970/1362 nt)									
BNA7							Y191* (TAC→TAA)	Y191* (TAC→TAA)	Y191* (TAC→TAA)						
COS111						P309R (CCA→CGA)									
COS7								D333E (GAC→GAG)							
CYC8							E365K (GAA→AAA)	E365K (GAA→AAA)							
DAN4											A1 bp. coding		E31* (GAA→TAA)		
DCK1											(3759/5799 nt)				
DOC1										G117E (GGA→GAA)					
ERG11						Facat						N114H (AAC→CAC)			
FMP30						E200° (GAA→TAA)				Magai					
GZF3				\$730						(ATG→ATT)	\\\/752*	\\\/752*			
HAL5				(TCA→TTA)						(TGG→TGA)	(TGG→TGA)	(TGG→TGA)			
HRD1							G105D	G105D				(CTT→CGT)			
KIC1							(GGT→GAT)	(GGT→GAT)		T510N					
										(ACC→AAC)	A16T				
										(T)5→4,	(GCT→ACT) (T)5→4,	(T)5→4,			
MM52								N581T		coding (81/444 nt)	coding (81/444 nt)	coding (81/444 nt)			
MPH2								(AAC→ACC)					(A)8→9,	(A)8→9,	(A)8→9,
MTC5													coding (2312/3447 nt)	coding (2312/3447 nt)	coding (2312/3447 nt)
NOG2		W325S (TGG→TCG)													
NRG1	∆1 bp, coding (652/696 nt)	∆1 bp, coding (652/696 nt)	Δ1 bp, coding (652/696 nt)	C176W (TGC→TGG)	C176W (TGC→TGG)	C176W (TGC→TGG)							H226N (CAT→AAT)	H226N (CAT→AAT)	H226N (CAT→AAT)
NTE1	A1552T (GCA→ACA)														
PFK1					K987* (AAA→TAA)										
PMD1										I218T (ATT→ACT)	I218T (ATT→ACT)	I218T (ATT→ACT)			
PSA1									G253R (GGT→CGT)						
RBK1										L299⊦ (TTG→TTT)			82561	82561	82561
RBS1									A325P				(TCG→TTG)	(TCG→TTG)	(TCG→TTG)
RPC40							W117R	W117R	(GCT→CCT)						
							(TGG→AGG)	(TGG→AGG)		(T)11→12,	(T)11→12,	(T)11→12,			
RP514A										pseudogene (169/542 nt)	pseudogene (169/542 nt) N699Y	pseudogene (169/542 nt)			
SAP155				M88V							(AAC→TAC)				
SUO2				(ATG→GTG)						L393F					
SILAS										(TTG→TTT) R91S					
TIF5						G29V			G31S	(AGG→AGT)					
TPO1						(GGT→GTT)			(GGT→AGT)				S156F	S156F	S156F
TUP1	N369K	N369K	N369K										(101→111)	(101→111)	(101→111)
UBS1	(1010 //001)	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						S122* (TCA→TAA)						
YGL239C_CDS													N6K (AAC→AAA)	N6K (AAC→AAA)	
YKR040C_CDS													(T)13→12, coding		
YLR227W-B	Δ5,584 bp, between Ty1												(483/549 fit)		
YLR466C-B	LTR	+T, coding	+T, coding				coding								
YMR027W		(42/11/10)	(42) 111 110				(42) 117 10)								L158M (CTG→ATG)
YMR144W											E189E (GAG→GAA)				
YPS6						A450S (GCT→TCT)									
YPT52															(CTTT)2→1, coding
VDTE2					G176D										nt)
VPD1	S535W	S535W	S535W		(GGC→GAC)										
(chromosome	(TCG→TGG)	(TCG→TGG)	(TCG→TGG)												duplication
)															(224000- 318000)
(chromosome XIII)									duplication (349000- 476000)						
(chromosome XIV)	7x coverage (364000- 415000)	7x coverage (364000- 415000)	7x coverage (364000- 415000)	6x coverage (373000- 429000)	6x coverage (373000- 429000)	5x coverage (373000- 429000)	5x coverage (371000- 427000)	5x coverage (371000- 427000)	8x coverage (373000- 429000)	6x coverage (373000- 429000)	6x coverage (373000- 429000)	7x coverage (373000- 429000)			

 Table S5. Comparison between genes affected by increased read coverage in chromosome XIV and Aro80p targets

Chromosome XIV ORFs	Aro80p targets from Yeastract
YNL141W, YNL140C, YNL139C, YNL138W-A, YNL138W, YNL137C, YNL136W, YNL135C, YNL134C, YNL133C, tF(GAA)N, YNL132W, YNL131W, YNL130C, YNL130C-A, YNL129W, YNL128W, YNL127W, YNL126W, <u>YNL125C</u> , YNL124W, YNL123W	YOR239W, YGR037C, YOL086C, YMR303C, YBR145W, YLR040C, YNR044W, YGL032C, YCR082W, YHL021C, YPR004C, YOR034C, YBR070C, YOL058W, YDR380W, YDR421W, YHR137W, YPL271W, YDR377W, YML081C-A, YOL077W-A, YPR020W, YNL259C, YKL146W, YDR046C, YLL015W, YHR208W, YJR148W, YOR078W, YFL023W, YLR062C, YKL005C, YOR276W, YGR140W, YAL033W, YOR257W, YBR028C, YML057W, YPR013C, YDL248W, YMR034W, YHR103W, YHR053C, YHR055C, YCL007C, YAL012W, YGR155W, YPL170W, YOR236W, YLR348C, YIR004W, YHR143W, YLR405W, YGR015C, YKL172W, YKL160W, YDR056C, YIL027C, YLL014W, YGR254W, YHR174W, YHR123W, YLR05U, YGR015C, YKL172W, YKL160W, YDR056C, YIL027C, YLL014W, YGR254W, YHL019W, YFR008W, YLR051C, YPR062W, YAL053W, YDR373W, YBL042C, YAL022C, YCL027W, YCL058C, YLR068W, YLR088W, YLR343W, YOL132W, YAL053W, YDR373W, YBL042C, YAL022C, YCL027W, YCL058C, YLR068W, YLR088W, YLR343W, YOL132W, YDR096W, YNL255C, YDL207W, YBR244W, YDR044W, YOR237W, YBR009C, YNL030W, YCL066W, YCR097W, YOR020C, YDR171W, YMR044W, YBR011C, YMR044W, YOR237W, YBR099C, YNL030W, YCL066W, YCR097W, YOR020C, YDR171W, YMR044W, YBR011C, YMR048W, YOR226C, YKL032C, YGL203C, YPR159W, YNL308C, YLR104W, YGL079C, YKL003C, YBL090W, YMR26W, YBR268W, YML009C, YMR158W, YKR077W, YHL036W, YHR072W-A, YNL110C, YPL043W, YPL146C, YOL144W, YOL069W, YDR192C, YKL120W, YOR13C, YER178W, YNL149C, YBR196C, YCR012W, YDR281C, YDL108C, YKL164C, YKR013W, YLL010C, YNL016W, YOR243C, YGR280C, YOR347C, YOR286W, YOR286W, YOL436C, YBL618C, YGR028C-A, YNL294C, YL1089C, YKL132C, YJR063W, YOR210W, YGL070C, YHR143W-A, YLR061W, YGL031C, YGR148C, YOL127W, YLR344W, YGR034W, YHR010W, YFR032C-A, YDL075W, YOR236W, YOL143C, YBR256C, YIL137C, YNR037C, YPL183W, YDL050C, YLR035C, YGR047C, YOR265W, YOR305W, YOR237C, YCR045C, YIL147C, YLR065W, YDR050C, YDL174C, YLR035C, YGR035W, YOR305W, YOR237C, YCR045W, YHL106W, YJL052W, YIL016W, YOR357C, YCR073W-A, YOR136C, YHL135W, YHR030C, YHR147C, YHL056W, YHR021C, YHR135W-A, YBR057C, YOR073W, YRR071C, YHR035C, YHR035C, YHR035C, YHL047C, YHL238W, YLR344W, YGR035C, YHR035C, YHL014C, YPL239W, YHR036C, YHR055C,

Strain	Genotype	Reference
CEN.PK113-7D	MATa MAL2-8c SUC2	P. Kötter
GL01	(CEN.PK113-7D) chrXI::P <sub>GAL1</sub> -GFP-T <sub>CYC1</sub> KANMX	(1)
IMX585	(CEN.PK113-7D) can1∆∷cas9-natNT2	(2)
ARO80_706	(IMX585) ARO80 <sup>S706T</sup>	this study
ARO80_910	(IMX585) ARO80 <sup>E910D</sup>	this study
NRG1_226	(IMX585) NRG1 <sup>H226N</sup>	this study
ESBP6_OE	(IMX585) chrX::PTEF1-ESBP6-TADH1	this study
ARO80_706+∆ESBP6	(IMX585) ARO80 <sup>S706T</sup> + ΔESBP6	this study
ARO80_910+∆ESBP6	(IMX585) ARO80 <sup>E910D</sup> + ΔESBP6	this study
ΔESBP6	(IMX585) ΔESBP6	this study
ΔPDR12	(IMX585) ΔPDR12	this study
ΔESBP6 + ΔPDR12	(IMX585) ΔESBP6 + ΔPDR12	this study
ESBP6_OE + ΔPDR12	(IMX585) chrX::PTEF1-ESBP6-TADH1 + ΔPDR12	this study
QL01	MATa ura3-52 can1∆::cas9-natNT2 TRP1 LEU2 HIS3 XII-2::(Р <sub>GPM1</sub> - AtPAL2-T <sub>FBA1</sub> )+(Ртднз-AtC4H-T <sub>CYC1</sub> )+Рнхт7-AtATR2- Т <sub>рҮХ212</sub> )+(Р <sub>РGK1</sub> -СҮВ5-Т <sub>АДН1</sub> )	(3)
QL01_ESBP6	(QL01) chrXI::PTEF1-ESBP6-TADH1-KIURA3	this study
QL01_URA	(QL01) chrXI::KIURA2	this study
QL38	$\begin{array}{l} MATa \; ura3-52 \; can1\Delta::cas9-natNT2 \; TRP1 \; LEU2 \; HIS3 \; gal7/10/1\Delta \\ gpp1\Delta \; XII-2::(\; P_{TDH3}-P_{tHXT7}-AtATR2-T_{pYX212})+(P_{PGK1}-CYB5-T_{ADH1}) \; X-3::(P_{TP11}-EcaroL-T_{pYX212})+(T_{ADH1}-ARO7^{G141S}-P_{TEF1})+(P_{PGK1}-ARO4^{K229L}-T_{CYC1}) \; X-4::(T_{CYC1}-ARO1-P_{TP11})+(P_{TDH3}-ARO2-T_{ADH1})+(T_{TDH2}-ARO3-P_{TEF1}) \; X-2::(P_{GPM1}-PHA2-T_{CYC1}) \; XI-1::(P_{GAL7}-F_{J}TAL-T_{IDP1})+(T_{CYC1}-AtC4H-P_{GAL2})+(P_{GAL1}-AtPAL2-T_{TPS1})+(T_{FBA1}-MtPDH1-P_{TDH3}) \; XII-5::(T_{ADH1}-Bbxfpk-P_{GAL1})+(P_{GAL2}-Ckpta-T_{CYC1}) \\ \end{array}$	(3)
QL38_ESBP6	(QL38) chrXI::PTEF1-ESBP6-TADH1-KIURA3	this study
QL38_URA	(QL38) chrXI::KIURA2	this study

# Table S7. List of primers used in this work

Number	Name	Sequence	Comment
1	pMEL_lin1	GATCATTTATCTTTCACTGCGGAGAAG	pMEL10 linearizing primer
2	pMEL_lin2	GTTTTAGAGCTAGAAATAGCAAGTTAAAAATAAGGCTAGTC	pMEL10 linearizing primer
3	pMEL_seq	CCAAGCGCGCAATTAACCCT	pMEL10 sequencing primer
4	ESBP6_targetRNA FW	TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCTTCTATCAGGATGA AATTAAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAAC	ESBP6 guide RNA insert primer for cloning into pMEL13
5	ESBP6_targetRNA RV	GTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTTAATTTCATCCTGA TAGAAGATCATTTATCTTTCACTGCGGAGAAGTTTCGAACGCCGAAACATGCGCA	ESBP6 guide RNA insert primer for cloning into pMEL13
6	ESBP6_repair oligo fw	CACTTTTCTTTACTTTTCTTTAGGTATAATTACGGGGGCTTCTGAAAATAAAT	ESBP6 deletion repair primer
7	ESBP6_repair oligo rv	TATGATGAGTAGGCGACGTAACTATCGCGTATATAACATGAATCAGGTCGTCGAAAAGAATTTT CAGATTTATTTTCAGAAGCCCCGTAATTATACCTAAAGAAAAGTAAAGAAAAGTG	ESBP6 deletion repair primer
8	ESBP6_dg fw	CGAGTGGTAGTGCCTGACTC	Colony PCR primer to confirm ESBP6 deletion
9	ESBP6_dg rv	CCTGGATCCGCAACACAAAG	Colony PCR primer to confirm ESBP6 deletion
10	PDR12_gRNA_fw	TGCGCATGTTTCGGCGTTCGAAACTTCTCCCGCAGTGAAAGATAAATGATCTTTCCCAAAAATTA CTGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAAC	PDR12 guide RNA insert primer for cloning into pMEL13
11	PDR12_gRNA_rv		PDR12 guide RNA insert primer for cloning into pMEL13
12	PDR12_KO_repair_fw		PDR12 deletion repair primer
13	PDR12_KO_repair_rv	AAAATTGAAAAATAAAAATTGTGTGTTAAACCACGAAATACAAATATATTTGCTTGC	PDR12 deletion repair primer
14	PDR12_out_fw	CGCAGGGATTCGGTATCACA	Colony PCR primer to confirm PDR12 deletion
15	PDR12_out_rv	ATTCAACGTGCGAAAGACGC	Colony PCR primer to confirm PDR12 deletion
16	ARO80_targetRNA_FW	TGCGCATGTTTCGGCGTTCGAAACTTCTCCCGCAGTGAAAGATAAATGATCGCATTTTACTATGA ACGCAAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAAC	ARO80 (site 706) guide RNA insert primer for cloning into pMEL13
17	ARO80_targetRNA_RV	GTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTTGCGTTCATAGTAA AATGCGATCATTTATCTTTCACTGCGGAGAAGTTTCGAACGCCGAAACATGCGCA	ARO80 (site 706) guide RNA insert primer for cloning into pMEL13
18	ARO80_S706T_repair_fw	GTTTCAAGGCAAGGAATGCTAAAATACATGCCCGTAAGATGGGTAATACGAATAATTAGAACTA TTGCGTTCATAGTAAAATGCTACCTAACACTTACTGGTAGTGAACTGGCAACAAAT	ARO80 S706T repair primer
19	ARO80_S706T_repair_rv	ATTTGTTGCCAGTTCACTACCAGTAAGTGTTAGGTAGCATTTTACTATGAACGCAATAGTTCTAA TTATTCGTATTACCCATCTTACGGGCATGTATTTTAGCATTCCTTGCCTTGAAAC	ARO80 S706T repair primer
20	ARO80_706_seq_fw	AAGCGCGAGGTATGTGGAAT	Sequencing primer to confirm the introduction of the point mutation S706T into ARO80
21	ARO80_910_seq_rv	ACGCGTTATTGGCCTTGAGT	Sequencing primer to confirm the introduction of the point mutation E910D into ARO80
22	ARO80_targetRNA FW	TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCAGGTCCATCTCTAT CTGACGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAAC	ARO80 (site 910) guide RNA insert primer for cloning into pMEL13
23	ARO80_targetRNA RV	GTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACCGTCAGATAGAGAT GGACCTGATCATTTATCTTTCACTGCGGAGAAGTTTCGAACGCCGAAACATGCGCA	ARO80 (site 910) guide RNA insert primer for cloning into pMEL13
24	ARO80_E910D_repair_f w	CTCTTCCAAGGTCCATCTCTATCTGACGAAGTTACAGATTGGTTCGGTGCTAGTGAAGATATCG GGCTTGAATTTGTAGAACCATGGACAGAACTTATTGATCAACGATATATGCAATGT	ARO80 E910D repair primer
25	ARO80_E910D_repair_rv	ACATTGCATATATCGTTGATCAATAAGTTCTGTCCATGGTTCTACAAATTCAAGCCCGATATCTT CACTAGCACCGAACCAATCTGTAACTTCGTCAGATAGAGATGGACCTTGGAAGAG	ARO80 E910D repair primer
26	NRG1_targetRNA FW	TGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCGAAAAAGGGACAA TAATTGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAAC	NRG1 (site 226) guide RNA insert primer for cloning into pMEL13
27	NRG1_targetRNA RV	GTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTCAATTATTGTCCCT TTTTCGATCATTTATCTTTCACTGCGGAGAAGTTTCGAACGCCGAAACATGCGCA	NRG1 (site 226) guide RNA insert primer for cloning into pMEL13
28	NRG1_H226N_repair_fw	TATAAGGGATGCACGCAGCGATTCAGTCGACATGATAATTGCTTGC	NRG1 H226N repair primer
29	NRG1_H226N_repair_rv	GTAGTACTGCTAATGAGAAAAACACGGGTATAGTGTCAATTATTGTCCCTTTTTCAAATTTGTTC TATAGTGTTGCAAGCAATTATCATGTCGACTGAATCGCTGCGTGCATCCCTTATA	NRG1 H226N repair primer
30	NRG1_seq_fw	TCTCTGAAAACGCGAAAGCAA	Sequencing primer to confirm the introduction of the point mutation H226N into NRG1
31	NRG1_seq_rv	AACCGCAAATGTCAAAAAGCCA	Sequencing primer to confirm the introduction of the point mutation H226N into NRG1
32	X2DOWN_fw	ctcgccaaggcattaccatc	amplification of X2 downstream region from plasmid pX2
33	X2DOWN_rv	tttgaagctatggtgtgtgccctgcataatcggcctcacag	amplification of X2 downstream region from plasmid pX2
34	X2_TEF1_fw	tgtgaggccgattatgcagggcacacaccatagcttcaaaatg	amplification of TEF1 promoter from pSPGM1
35	ESBP_TEF1_rv	GAGTGCGTTGACATTGTTTTTGTAATTAAAACTTAGATTAGATTGCTATGCTTTC	amplification of TEF1 promoter from pSPGM1
36	ESBP_fw	AGTTTTAATTACAAAAAACAATGTCAACGCACTCAAACGACTAC	amplification of ESBP6 coding sequence from the genome
37	ESBP_rv	AGTGTCAACAACGTATCTACCTAGACCTTCATTGGATATACCATTCTTAG	amplification of ESBP6 coding sequence from the genome
38	ESBP_X2UP_ADH1_fw	TATATCCAATGAAGGTCTAGGTAGATACGTTGTTGACACTTCTAAATAAGCG	amplification of ADH1 terminator and X2 upstream region from
39	X2UP_ADH1_rv	cgtctatgaggagactgttagttgga	amplification of ADH1 terminator and X2 upstream region from
40	check_X2_UP_out	ACAATGTAGTAGTAGTAGCAGCAGATTC	plasmids pX2 flanking primer for region X2 for colony PCR and sequencing
41	check_X2_DOWN ou	TTCCATCGTCGGTTGTACGC	flanking primer for region X2 for colony PCR and sequencing
42	XI5-UP FW	GCGGAGAAGTCGTTGATAGC	amplification of XI5 upstream region and ADH1 terminator from
43	ADH1 BEGIN RV	GTAGATACGTTGTTGACACTTC	plasmid pXI-5 amplification of XI5 upstream region and ADH1 terminator from
44	TEF1_BEGIN_FW	GCACACACCATAGCTTCAAAATGTTT	plasmid pXI-5 amplification of TEF1 promoter, ESBP6 CDS and ADH1 terminator
45	ADH1_END_RV	GAGCGACCTCATGCTATACCTGAG	amplification of TEF1 promoter, ESBP6 CDS and ADH1 terminator
46		GATCATAGATCCGGCACTTAGAGAAA	trom the ESBP6 overexpression strain amplification of KIURA3 marker and the XI5 downstream region
17		TIGTAATTAAAACTTACATTACATTACATTACTTAC	from plasmid pIRP01 amplification of KIURA3 marker and the XI5 downstream region
47	check_XI5_fw	GTTCCTACACGCCATTTGAC	from plasmid pIRP01 flanking primer for region XI5 for colony PCR and sequencing

Table S8. List of plasmids used in this work

Plasmid	Main features	Reference
pMEL13	Template for gRNA plasmids	(2)
pMEL13-ARO80-706	gRNA for ARO80 <sup>S706T</sup> (pMEL13)	this study
pMEL13-ARO80-910	gRNA for ARO80 <sup>E910D</sup> (pMEL13)	this study
pMEL13-NRG1-226	gRNA for NRG1 <sup>H226N</sup> (pMEL13)	this study
pMEL13-ESBP6-KO	gRNA for deleting ESBP6 (pMEL13)	this study
pMEL13-PDR12-KO	gRNA for deleting PDR12 (pMEL13)	this study
рХ-2	template for site X2 up/downstream regions	(10)
pSPGM1	Template for TEF1/PGK1 promoters	(11)
pQC059	gRNA for X2 site (pROS13)	(3)
pIRP01	template for site XI-5 up/downstream regions	(12)
pXI-5	template for site XI-5 up/downstream regions	(10)

# **SI References**

- 1. R. Pereira, *et al.*, Adaptive laboratory evolution of tolerance to dicarboxylic acids in Saccharomyces cerevisiae. *Metab. Eng.* 56, 130–141 (2019).
- 2. R. Mans, *et al.*, CRISPR/Cas9: a molecular Swiss army knife for simultaneous introduction of multiple genetic modifications in Saccharomyces cerevisiae. *FEMS Yeast Res.* 15 (2015).
- 3. Q. Liu, *et al.*, Rewiring carbon metabolism in yeast for high level production of aromatic chemicals. *Nat. Commun.* 10 (2019).
- 4. H. Inoue, H. Nojima, H. Okayama, High efficiency transformation of Escherichia coli with plasmids. *Gene* 96, 23–28 (1990).
- 5. J. Sambrook, *Molecular cloning : a laboratory manual* (Third edition. Cold Spring Harbor, N.Y. : Cold Spring Harbor Laboratory Press, [2001] ©2001).
- 6. D. Solis-Escalante, *et al.*, *amdSYM*, a new dominant recyclable marker cassette for Saccharomyces cerevisiae. FEMS Yeast Res. 13, 126–139 (2013).
- 7. C. Verduyn, E. Postma, W. A. Scheffers, J. P. Van Dijken, Effect of benzoic acid on metabolic fluxes in yeasts: A continuous-culture study on the regulation of respiration and alcoholic fermentation. *Yeast* 8, 501–517 (1992).
- 8. J. Quan, J. Tian, Circular Polymerase Extension Cloning of Complex Gene Libraries and Pathways. *PLoS One* 4, e6441 (2009).
- 9. R. D. Gietz, R. A. Woods, "Yeast Transformation by the LiAc/SS Carrier DNA/PEG Method" in *Yeast Protocols*, (Humana Press, 2006), pp. 107–120.
- 10. M. D. Mikkelsen, *et al.*, Microbial production of indolylglucosinolate through engineering of a multi-gene pathway in a versatile yeast expression platform. *Metab. Eng.* 14, 104–111 (2012).
- 11. Y. Chen, S. Partow, G. Scalcinati, V. Siewers, J. Nielsen, Enhancing the copy number of episomal plasmids in Saccharomyces cerevisiae for improved protein production. *FEMS Yeast Res.* 12, 598–607 (2012).
- 12. J. López, *et al.*, Production of β-ionone by combined expression of carotenogenic and plant CCD1 genes in Saccharomyces cerevisiae. *Microb. Cell Fact.* 14, 84 (2015).
- 13. E. T. Mohamed, *et al.*, Generation of a platform strain for ionic liquid tolerance using adaptive laboratory evolution. *Microb. Cell Fact.* 16, 204 (2017).
- 14. T. E. Sandberg, *et al.*, Evolution of Escherichia coli to 42 °C and Subsequent Genetic Engineering Reveals Adaptive Mechanisms and Novel Mutations. *Mol. Biol. Evol.* 31, 2647–2662 (2014).
- 15. D. E. Deatherage, J. E. Barrick, "Identification of Mutations in Laboratory-Evolved Microbes from Next-Generation Sequencing Data Using breseq" in (Humana Press, New York, NY, 2014), pp. 165–188.
- 16. B. Langmead, S. L. Salzberg, Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 9, 357–359 (2012).
- 17. P. Jenjaroenpun, *et al.*, Complete genomic and transcriptional landscape analysis using third-generation sequencing: a case study of Saccharomyces cerevisiae CEN.PK113-7D. *Nucleic Acids Res.* (2018) https://doi.org/10.1093/nar/gky014 (January 16, 2018).
- 18. T. D. Otto, G. P. Dillon, W. S. Degrave, M. Berriman, RATT: Rapid Annotation Transfer Tool. *Nucleic Acids Res.* 39, e57–e57 (2011).